Switch to:

Biomarin Pharmaceutical EBIT

: $-102 Mil (TTM As of Sep. 2019)
View and export this data going back to 1999. Start your Free Trial

Biomarin Pharmaceutical's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2019 was $16 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2019 was $-102 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biomarin Pharmaceutical's annualized ROC % for the quarter that ended in Sep. 2019 was 2.86%. Biomarin Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was 3.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -0.83%.


Biomarin Pharmaceutical EBIT Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -91.56 -119.77 -794.92 3.11 -102.65

Biomarin Pharmaceutical Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.29 -36.16 -46.23 -35.50 16.10

Biomarin Pharmaceutical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then operating income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2019 was -36.157 (Dec. 2018 ) + -46.23 (Mar. 2019 ) + -35.495 (Jun. 2019 ) + 16.098 (Sep. 2019 ) = $-102 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Biomarin Pharmaceutical  (NAS:BMRN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biomarin Pharmaceutical's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC %(Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income*(1-Tax Rate)/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/2)
=16.04 * ( 1 - -460.33% )/( (3079.181 + 3207.453)/2)
=89.876932/3143.317
=2.86 %

where

Invested Capital(Q: Jun. 2019 )
=Book Value of Debt + Book Value of Equity - Cash
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation + Total Stockholders Equity - Cash
=839.165 + 10.165 + 2960.954 - 731.103
=3079.181

Invested Capital(Q: Sep. 2019 )
=Book Value of Debt + Book Value of Equity - Cash
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation + Total Stockholders Equity - Cash
=843.616 + 10.225 + 3074.405 - 720.793
=3207.453

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) operating income data.

2. Joel Greenblatt's definition of Return on Capital:

Biomarin Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/2 )
=64.392/( ( (962.97 + max(646.402, 0)) + (969.3 + max(655.046, 0)) )/2 )
=64.392/( ( 1609.372 + 1624.346 )/2 )
=64.392/1616.859
=3.98 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(377.15 + 578.736 + 119.779) - (321.729 + 0 + 107.534)
=646.402

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(402.97 + 609.049 + 126.547) - (342.74 + 0 + 140.78)
=655.046

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Biomarin Pharmaceutical's Earnings Yield (Joel Greenblatt) %for the quarter that ended in Sep. 2019 is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2019 )
=-101.784/12238.088
=-0.83 %

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Biomarin Pharmaceutical EBIT Related Terms


Biomarin Pharmaceutical EBIT Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)